Yung-Jue Bang
New Generation University College
667 Papers
5.5K Citations
Yung-Jue Bang is an academic researcher from New Generation University College. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 94, co-authored 664 publications. Previous affiliations of Yung-Jue Bang include Seoul National University Hospital & Seoul National University.
Chat about Author
Papers
The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
Kohei Shitara,Mustafa Ozguroglu,Yung-Jue Bang,Maria Di Bartolomeo,Mario Mandalà,Min-Hee Ryu,Caterina Vivaldi,Tomasz Olesinski,Hyun Cheol Chung,Kei Muro,Eric Van Cutsem,J. Kobie,Razvan Cristescu,Deepti Aurora-Garg,Jia Lu,Chie-Schin Shih,David Adelberg,Z. Alexander Cao,David Fabrizio,Charles S. Fuchs +19 more
TL;DR: In this paper, a randomized, open-label, phase 3 study of pembrolizumab vs paclitaxel in pts with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma w...
Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution
Byoung Hyuck Kim,Kyubo Kim,Eui Kyu Chie,Jeanny Kwon,Jin-Young Jang,Sun Whe Kim,Do Youn Oh,Yung-Jue Bang +7 more
TL;DR: Adjuvant chemoradiotherapy after PD for DCC is an effective and tolerable strategy without significant side effects and prognosis of DCC was mainly influenced by histologic differentiation and LN metastasis.
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
Yung-Jue Bang,Wu Chou Su,Martin Schuler,Do-Hyun Nam,Wan-Teck Lim,Todd M. Bauer,Analia Azaro,Ronnie Tung-Ping Poon,David S. Hong,Chia-Chi Lin,Mikhail Akimov,Samson Ghebremariam,Sylvia Zhao,Monica Giovannini,Brigette B.Y. Ma +14 more
TL;DR: Capmatinib was well tolerated and showed antitumor activity and acceptable safety profile at the RP2D, and the recommended phase 2 dose was 600 mg bid capsule/400 mg bid tablet.
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
Yung-Jue Bang,Seock-Ah Im,Keun Wook Lee,Jae Yong Cho,Eun Kee Song,Kyung Hee Lee,Yeul Hong Kim,Joon Oh Park,Hoo Geun Chun,Dae Young Zang,Anitra Fielding,Jacqui Rowbottom,Darren Hodgson,Mark J. O'Connor,Xiaolu Yin,Woo Ho Kim +15 more
TL;DR: Olaparib/paclitaxel is active in the treatment of patients with metastatic gastric cancer, with a greater OS benefit in ATMlow patients.
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
TL;DR: It is observed that co-targeting of WEE1 and ATM acted synergistically to reduce cell proliferation and migration, and to induce DNA damage in vitro, suggesting dual blockade of Wee1 and ATM might be a potential therapeutic strategy for PC.